We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View
Read MoreHide Full Article
Merck & Co., Inc. (MRK - Free Report) reported third-quarter 2016 earnings of $1.07 per share, comfortably surpassing the Zacks Consensus Estimate of 98 cents and increasing approximately 12% from the year-ago period.
Again, revenues for the quarter were up 5% to $10.54 billion, beating the Zacks Consensus Estimate of $10.24 billion. Reported revenues included an estimated benefit of about $150 million of additional sales in Japan resulting from the timing of shipments in anticipation of a resource planning system that the company will implement in the fourth quarter of 2016.
Currency movement negatively impacted revenues by 1%.
Quarter in Detail
Merck’s Pharmaceutical segment posted revenues of $9.4 billion, up 6% year over year. Products like Keytruda, Gardasil/Gardasil 9 and ProQuad performed well. Keytruda brought in sales of $356 million in the third quarter of 2016, up from $314 million in the second quarter of 2016. Sales continued to be driven by new indications and geographical expansion.
Zetia/Vytorin sales inched up 1% to $944 million, reflecting higher sales in Japan due to the timing of shipments. Zetia is expected to lose market exclusivity in the U.S. in Dec 2016 and sales are expected to decline significantly thereafter.
Gardasil/Gardasil 9 sales surged 38% to $860 million, indicating the timing of public sector purchases, and higher pricing and demand in the U.S.
Recently launched hepatitis C virus treatment, Zepatier, brought in sales of $164 million, up from $112 million in the second quarter of 2016.
Meanwhile, sales of Remicade (lost exclusivity in Europe and facing stiff biosimilar competition in the region), Nasonex (generic version launched in the U.S. in Mar 2016), Cubicin (lost patent protection in the U.S. in Jun 2016), Januvia/Janumet and Isentress recorded a decline.
Merck’s Animal Health segment posted revenues of $865 million, up 5% from the year-ago quarter.
Marketing and administrative (M&A) expenses declined 3% to $2.4 billion in the third quarter of 2016, reflecting lower selling costs and promotional spending due to prioritizing investments in key brands and the favorable foreign exchange movement.
Research and development (R&D) spend increased 5% to $1.6 billion in the quarter, reflecting higher clinical development spending.
2016 Guidance Upped
Merck narrowed and raised its 2016 guidance for both earnings and revenues. The company now expects earnings in the range of $3.71 to $3.78 per share, including approximately 1% negative foreign exchange impact. At the time of releasing second-quarter 2016 results, the company had guided earnings of $3.67–$3.77 per share, including around 1% negative foreign exchange impact.
Merck now expects revenue in the range of $39.7–$40.2 billion, including negative currency impact of approximately 2%. At the time of releasing second-quarter 2016 results, the company had guided revenues of $39.1–$40.1 billion, including negative foreign exchange impact of approximately 2%.
The Zacks Consensus Estimate for earnings stands at $3.74 on revenues of $39.65 billion, respectively.
Meanwhile, Merck continues to expect a year-over-year decline in M&A spend and an increase in R&D spend. The company had spent $6.6 billion and $9.8 billion on R&D and M&A, respectively, in 2015.
Merck delivered better-than-expected third-quarter 2016 results with both the top and the bottom line surpassing expectations. The top line will, however, remain under pressure mainly due to increased competition as well as generic entry. The company will thus continue to pursue cost-cutting initiatives to drive the bottom line.
Nevertheless, we are encouraged by the company’s efforts to expand its pipeline and focus on core areas of expertise. The company has made significant progress with its pipeline and is working on bringing new products to market. New products like Keytruda should continue to contribute meaningfully to the top line.
Incyte’s earnings estimates for 2016 and 2017 were up a respective 10% and 2.8% over the last 60 days. The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335.16%.
Exelixis has an average positive surprise of 9.10% over the trailing four quarters. Its share price has jumped 100.2% year to date. The loss estimates for both 2016 and 2017 have narrowed down over the past 60 days.
Loss estimates for BioMarin have narrowed from 28 cents to 25 cents for 2016 and from $1.16 to $1.11 for 2017 over the last 60 days.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View
Merck & Co., Inc. (MRK - Free Report) reported third-quarter 2016 earnings of $1.07 per share, comfortably surpassing the Zacks Consensus Estimate of 98 cents and increasing approximately 12% from the year-ago period.
Again, revenues for the quarter were up 5% to $10.54 billion, beating the Zacks Consensus Estimate of $10.24 billion. Reported revenues included an estimated benefit of about $150 million of additional sales in Japan resulting from the timing of shipments in anticipation of a resource planning system that the company will implement in the fourth quarter of 2016.
Currency movement negatively impacted revenues by 1%.
Quarter in Detail
Merck’s Pharmaceutical segment posted revenues of $9.4 billion, up 6% year over year. Products like Keytruda, Gardasil/Gardasil 9 and ProQuad performed well. Keytruda brought in sales of $356 million in the third quarter of 2016, up from $314 million in the second quarter of 2016. Sales continued to be driven by new indications and geographical expansion.
Zetia/Vytorin sales inched up 1% to $944 million, reflecting higher sales in Japan due to the timing of shipments. Zetia is expected to lose market exclusivity in the U.S. in Dec 2016 and sales are expected to decline significantly thereafter.
Gardasil/Gardasil 9 sales surged 38% to $860 million, indicating the timing of public sector purchases, and higher pricing and demand in the U.S.
Recently launched hepatitis C virus treatment, Zepatier, brought in sales of $164 million, up from $112 million in the second quarter of 2016.
Meanwhile, sales of Remicade (lost exclusivity in Europe and facing stiff biosimilar competition in the region), Nasonex (generic version launched in the U.S. in Mar 2016), Cubicin (lost patent protection in the U.S. in Jun 2016), Januvia/Janumet and Isentress recorded a decline.
Merck’s Animal Health segment posted revenues of $865 million, up 5% from the year-ago quarter.
Marketing and administrative (M&A) expenses declined 3% to $2.4 billion in the third quarter of 2016, reflecting lower selling costs and promotional spending due to prioritizing investments in key brands and the favorable foreign exchange movement.
Research and development (R&D) spend increased 5% to $1.6 billion in the quarter, reflecting higher clinical development spending.
2016 Guidance Upped
Merck narrowed and raised its 2016 guidance for both earnings and revenues. The company now expects earnings in the range of $3.71 to $3.78 per share, including approximately 1% negative foreign exchange impact. At the time of releasing second-quarter 2016 results, the company had guided earnings of $3.67–$3.77 per share, including around 1% negative foreign exchange impact.
Merck now expects revenue in the range of $39.7–$40.2 billion, including negative currency impact of approximately 2%. At the time of releasing second-quarter 2016 results, the company had guided revenues of $39.1–$40.1 billion, including negative foreign exchange impact of approximately 2%.
The Zacks Consensus Estimate for earnings stands at $3.74 on revenues of $39.65 billion, respectively.
Meanwhile, Merck continues to expect a year-over-year decline in M&A spend and an increase in R&D spend. The company had spent $6.6 billion and $9.8 billion on R&D and M&A, respectively, in 2015.
MERCK & CO INC Price, Consensus and EPS Surprise
MERCK & CO INC Price, Consensus and EPS Surprise | MERCK & CO INC Quote
Our Take
Merck delivered better-than-expected third-quarter 2016 results with both the top and the bottom line surpassing expectations. The top line will, however, remain under pressure mainly due to increased competition as well as generic entry. The company will thus continue to pursue cost-cutting initiatives to drive the bottom line.
Nevertheless, we are encouraged by the company’s efforts to expand its pipeline and focus on core areas of expertise. The company has made significant progress with its pipeline and is working on bringing new products to market. New products like Keytruda should continue to contribute meaningfully to the top line.
Zacks Rank & Key Picks
Merck currently carries a Zacks Rank #2 (Buy). Some favorably placed stocks in the health care sector include BioMarin Pharmaceutical Inc. (BMRN - Free Report) , Exelixis, Inc. (EXEL - Free Report) and Incyte Corporation (INCY - Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Incyte’s earnings estimates for 2016 and 2017 were up a respective 10% and 2.8% over the last 60 days. The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335.16%.
Exelixis has an average positive surprise of 9.10% over the trailing four quarters. Its share price has jumped 100.2% year to date. The loss estimates for both 2016 and 2017 have narrowed down over the past 60 days.
Loss estimates for BioMarin have narrowed from 28 cents to 25 cents for 2016 and from $1.16 to $1.11 for 2017 over the last 60 days.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>